| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_178dbdb49e010afd7db6ebabb4cb4b5d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b5d62b24bd9ee041f521ff3177003b86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5132f3b7fa7a18c505bb474d716bb549
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c2db221f0094a7101b48ac9a0466233c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-241 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2007-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9906e7d4a16afb246bde5addbf616d82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ec84e4240867a24cc287bc587102770
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6dae065d0ed83dd8badc1f91402d9871 |
| publicationDate |
2007-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2007114680-A1 |
| titleOfInvention |
Anti-inflammatory protein ophthalmic preparation |
| abstract |
The invention relates to novel ophthalmic compositions for topical use with proven stability whose active principle is a molecule of protein type capable of blocking the activity of cytokines or factors involved in ophthalmic processes of inflammatory type or of angiogenic type or acute transplant rejection. Amongst the pro-inflammatory cytokines, a special role is played by tumour necrosis factor alpha (TNFα) and vascular endothelial growth factor (VEGF) as potent angiogenic agent, and therefore particular preference is given to compositions whose active principle is proteins that neutralize the biological activity of these two cytokines. The active proteins may be natural or recombinant, monoclonal or polyclonal antibodies or biologically active fragments thereof that comprise Fv, Fab, F(ab')2 or scFv, and that are capable of preventing or minimizing the phenomenon of the rejection of biological tissue grafts, particularly ocular tissue, including the cornea. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8821874-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10538577-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010062857-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8491905-B2 |
| priorityDate |
2006-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |